The global bradykinin mediated angioedema market size was valued at USD 6.97 billion in 2025 and is expected to reach USD 10.21 billion by 2033, at a CAGR of 4.90% during the forecast period
The market growth is largely fueled by increasing prevalence of hereditary angioedema (HAE) and other bradykinin-mediated conditions, coupled with rising awareness among healthcare professionals and patients regarding early diagnosis and treatment options
Furthermore, the growing adoption of innovative therapies, such as C1-inhibitor replacement, bradykinin receptor antagonists, and kallikrein inhibitors, is enhancing patient outcomes and expanding treatment accessibility. These converging factors are accelerating the uptake of Bradykinin Mediated Angioedema solutions, thereby significantly boosting the industry’s growth
